Danaher Co. (NYSE:DHR) Shares Bought by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA lifted its stake in shares of Danaher Co. (NYSE:DHR) by 22.7% during the 2nd quarter, HoldingsChannel reports. The fund owned 3,047,728 shares of the conglomerate’s stock after acquiring an additional 563,546 shares during the period. Massachusetts Financial Services Co. MA’s holdings in Danaher were worth $761,475,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of DHR. Gilbert & Cook Inc. lifted its holdings in shares of Danaher by 4.9% during the 4th quarter. Gilbert & Cook Inc. now owns 1,830 shares of the conglomerate’s stock worth $423,000 after acquiring an additional 86 shares during the period. Accretive Wealth Partners LLC lifted its holdings in shares of Danaher by 12.9% during the 4th quarter. Accretive Wealth Partners LLC now owns 3,632 shares of the conglomerate’s stock worth $840,000 after acquiring an additional 414 shares during the period. Gryphon Financial Partners LLC lifted its holdings in shares of Danaher by 19.1% during the 4th quarter. Gryphon Financial Partners LLC now owns 2,917 shares of the conglomerate’s stock worth $675,000 after acquiring an additional 468 shares during the period. TrinityPoint Wealth LLC raised its holdings in Danaher by 12.4% in the fourth quarter. TrinityPoint Wealth LLC now owns 1,469 shares of the conglomerate’s stock valued at $340,000 after buying an additional 162 shares during the period. Finally, Hillsdale Investment Management Inc. raised its holdings in Danaher by 38.7% in the fourth quarter. Hillsdale Investment Management Inc. now owns 215 shares of the conglomerate’s stock valued at $50,000 after buying an additional 60 shares during the period. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the transaction, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the transaction, the chief financial officer now owns 29,407 shares in the company, valued at approximately $8,229,254.88. The disclosure for this sale can be found here. Insiders have sold 39,659 shares of company stock worth $11,042,433 over the last 90 days. 11.10% of the stock is owned by company insiders.

Danaher Price Performance

Shares of Danaher stock opened at $276.06 on Tuesday. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The company’s 50-day moving average price is $265.25 and its two-hundred day moving average price is $256.67. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $281.70. The stock has a market cap of $199.37 billion, a PE ratio of 46.79, a price-to-earnings-growth ratio of 4.48 and a beta of 0.83.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.15. The business had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company’s revenue was down 2.9% compared to the same quarter last year. During the same period last year, the company posted $2.05 EPS. As a group, sell-side analysts anticipate that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be given a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.39%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Analyst Upgrades and Downgrades

Several research firms recently commented on DHR. Robert W. Baird raised their price target on shares of Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Evercore ISI decreased their price target on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. Bank of America raised their price target on shares of Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Finally, The Goldman Sachs Group lifted their price objective on shares of Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and an average price target of $278.94.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.